Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1663-1671

  Vokes, E E ^a   Mick, R ^a   Kies, M S ^a   Dolan, M E ^a   Malone, D ^a   Athanasiadis, I ^a   Haraf, D J ^a   Kozloff, M ^a   Weichselbaum, R R ^a   Ratain, M J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; ALPHA2B INTERFERON; CISPLATIN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; TETRAHYDROFOLIC ACID DERIVATIVE;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATITIS; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MUCOSA INFLAMMATION; PHARMACODYNAMICS; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 9244255891     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1663     Document Type: Article

References (49)

1. Vokes EE, Weichselbaum RR, Lippman S, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
2. Stupp R, Weichselbaum RR, Vokes EE: Combined modality therapy of head and neck cancer. Semin Oncol 21:349-358, 1994
3. Rooney M, Kish J, Jacobs J, et al: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 55:1123-1128, 1985
4. Vokes EE, Mick R, Lester EP, et al: Cisplatin and 5-fluorouracil does not yield long-term benefit in locally advanced head and neck cancer: Results from a single institution. J Clin Oncol 9:1376-1384, 1991
5. Thyss A, Schneider M, Santini J, et al: Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 54:755-760, 1986
6. Department of Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324:1685-1690, 1991
7. Laramore GE, Scott CB, Al-Sarraf M, et al: Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on Intergroup study. Int J Radiat Oncol Biol Phys 23:705-713, 1992
8. Paccagnella A, Orlando A, Marchiori C, et al: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 86:265-272, 1994
9. Vokes EE, Moran WJ, Mick R, et al: Neoadjuvant and adjuvant methotrexate, cisplatin, and fluorouracil in multimodal therapy of head and neck cancer. J Clin Oncol 7:838-845, 1989
10. Vokes EE, Panje WR, Schilsky RL, et al: Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: A phase I-II study. J Clin Oncol 7:761-768, 1989
11. Vokes EE, Choi KE, Schilsky RL, et al: Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 6:618-626, 1988
12. Vokes EE, Schilsky RL, Weichselbaum RR, et al: Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 8:241-247, 1990
13. Dreyfuss AI, Clark JR, Wright JE, et al: Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 112:167-172, 1990
14. Pfister DG, Bajorin D, Motzer R, et al: Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 120:89-95, 1994
15. Vokes EE, Ratain MJ, Mick R, et al: Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 11:360-368, 1993
16. Vokes EE, Weichselbaum RR, Mick R, et al: Favorable long-term survival following induction chemotherapy with PFL and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 84:877-882, 1992
17. Vokes EE, Kies M, Haraf DJ, et al: Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 13:876-883, 1995
18. Grogan L, Sotos GA, Allegra CJ: Leucovorin modulation of fluorouracil. Oncol 7:63-72, 1993
19. Straw JA, Szapary D, and Wynn WT: Pharmacokinetics of the diastereoisomers of leucovorin after intravenous and oral administration to normal subjects. Cancer Res 44:3114-3119, 1984
20. Schilsky RL, Ratain MJ: Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration. J Natl Cancer Inst 82:1411-1415, 1990
21. Zittoun J: Pharmacokinetics and in vitro studies of l-leucovorin. Comparison with the d and d,I-leucovorin. Ann Oncol 4:S1-S5, 1993 (suppl 2)
22. Milano G, Roman P, Khater R, et al: Dose versus pharmacokinetics for predicting tolerance to 5-day continuous infusion of 5-FU. Int J Cancer 41:537-541, 1988
23. Santini J, Milano G, Thyss A, et al: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
24. Milano G, Etienne MC, Cassuto-Viguier E, et al: Influence of sex and age on fluorouracil clearance. J Clin Oncol 10:1171-1175, 1992
25. Milano G, Etienne MC, Renee N, et al: Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 12:1291-1295, 1994
26. American Joint Committee on Cancer: Manual for Staging of Cancer (ed 3). Philadelphia, PA, Lippincott, 1988, pp 25-62
27. Harris BE, Song R, Soong S-J, et al: Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving 5-fluorouracil by protracted continuous infusion. Cancer Res 50:197-201, 1990
28. Tuchman M, Roemling RV, Hrushesky WAM, et al: Dihydropyrimidine dehydrogenase activity in human blood mononuclear cells. Enzyme 42:14-24, 1989
29. Bradford MM: A rapid and sensitive method for the quamitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976
30. Siegel S: Nonparametric Statistics for the Behavioral Sciences. New York, NY, McGraw-Hill, 1956
31. Port RE, Daniel B, Ding RW, et al: Relative importance of dose, body surface area, sex, and age for 5-fluorouracil clearance. Oncology 48:277-281, 1991
32. Stein BN, Petrelli NJ, Douglass HO, et al: Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 75:11-17, 1995
33. Bertrand R, Jolivet J: Lack of interference by the unnatural isomer of 5-formyltetrahydrofolate with the effects of the natural isomer in leucovorin preparations. J Natl Cancer Inst 81:1175-1178, 1989
34. Boarman DM, Allegra CJ: Intracellular metabolism of 5-formyl tetrahydrofolate in human breast and colon cell lines. Cancer Res 52:36-44, 1992
35. Valone FH, Gandara DR, Luce JA, et al: Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies. Cancer Chemother Pharmacol 32(3):215-220, 1993
36. Schneider M, Etienne MC, Milano G, et al: Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: A pharmacokinetic and clinical survey. J Clin Oncol 13:1656-1662, 1995
37. Zhang R, Zhihong L, Liu T, et al: Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: Possible relevance to fluoropyrimidine chemotherapy. Cancer Res 53:2816-2822, 1993
38. Petit E, Milano G, Levi F, et al: Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 48:1676-1679, 1988
39. Fleming RA, Milano G, Thyss A, et al: Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients. Cancer Res 52:2899-2902, 1992
40. Etienne MC, Lagrange JL, Dassonville O, et al: Population study of dihydropyrimidine dehydrogenase in cancer patients. J Clin Oncol 12:2248-2253, 1994
41. Diasio RB, Lu Z: Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol 12:2239-2242, 1994 (editorial)
42. Harris BE, Carpenter JT, Diasio RB: Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. Cancer 68:499-501, 1991
43. Lu Z, Zhang R, Diasio RB: Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 53:5433-5438, 1993
44. Etienne MC, Chéradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13:1663-1670, 1995
45. Milano G, Fischel JL, Etienne MC, et al: Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: Experimental data on human tumor cell lines. Cancer Chemother Pharmacol 34:147-152, 1994
46. Wadler S, Schwartz EL: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473-3486, 1990
47. Houghton JA, Adkins DA, Rahman A, et al: Interaction between 5-fluorouracil, leucovorin, and recombinant human interferon-α2a in cultured colon adenocarcinoma cells. Cancer Commun 3:225-231, 1991
48. Allegra CJ: Biochemical modulation: A modality that has come of therapeutic age. J Clin Oncol 9:1723-1726, 1991
49. Vlock DR, Johnson J, Myers E, et al: Preliminary trial of nonrecombinant interferon alpha in recurrent squamous cell carcinoma of the head and neck. Head Neck 13:15-21, 1991